17 patents currently held
68 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Sep 2029. from the record
Of the 68 now held by other companies, 28 name Novartis AG as their current owner, and 40 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Sep 2029
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2034 · High confidence
Also notable
Ends Mar 2030 · High confidence
Also notable
Ends Aug 2032 · High confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Mar 2031 · High confidence
Also notable
Ends Mar 2032 · High confidence
Also notable
Ends Dec 2034 · High confidence
Also notable
Ends Nov 2030 · High confidence
Peptides and Compositions for Treatment of Joint Damage
US 9,301,971
Cited by 20 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators
US 9,238,646
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Compounds and Compositions as C-Kit Kinase Inhibitors
US 8,569,283
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2032.
Compounds and Compositions as TRK Inhibitors
US 9,102,671
The most cited patent in this portfolio, cited by 61 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2032.
Compounds That Expand Hematopoietic Stem Cells
US 9,580,426
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2031.
Compositions and Methods for Modulating FXR
US 9,150,568
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2032.
Compounds and Compositions for the Treatment of Parasitic Diseases
US 9,303,034
The largest patent family in this portfolio, 6 related applications, renewed at every maintenance window due so far. Protection runs to 2034.
Compounds and Compositions for the Treatment of Parasitic Diseases
US 9,469,645
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Jul 2031 · High confidence
Cited by 20 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Array Biopharma, Inc.
Also notable
Ends Aug 2032 · High confidence
Cited by 38 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
now held by Novartis AG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 11, 2027The maintenance fee for Compounds and Compositions as TRK Inhibitors (US 9,102,671) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Markers Associated with WNT Inhibitors (US 10,422,007) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Compositions and Methods for Modulating FXR (US 9,150,568) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 2 fees due Jun 1 to 22, 2027 · next Jun 1
- 1 fee due Jul 19, 2027The maintenance fee for N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators (US 9,238,646) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 2 fees due Aug 6 to 13, 2027 · next Aug 6
- 2 fees due Oct 5, 2027
Recent changes
- 3 terms have ended since Aug 23, 2026
- Oct 28 US 8,871,754 Compounds and Compositions for the Treatment of Parasitic Diseases · lapsed on the fee record
- Sep 26 US 7,563,894 Diarylamine-Containing Compounds and Compositions, and Their Use as Modulators of C-Kit Receptors · term ended
- Sep 26 US 7,514,447 Diarylamine-Containing Compounds and Compositions, and Their Use as Modulators of C-Kit Receptors · term ended
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,216,964 | Hedgehog Pathway Modulators held by Novartis AG In force · High confidence | In force | High confidence | |
| US 9,238,646 | N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators held by Novartis AG In force · High confidence | In force | High confidence | |
| US 9,469,645 | Compounds and Compositions for the Treatment of Parasitic Diseases held by Novartis AG In force · High confidence | In force | High confidence | |
| US 9,580,426 | Compounds That Expand Hematopoietic Stem Cells held by The Scripps Research Institute In force · High confidence | In force | High confidence | |
| US 9,365,506 | Compounds and Compositions as TLR2 Agonists In force · High confidence | In force | High confidence | |
| US 9,150,568 | Compositions and Methods for Modulating FXR In force · High confidence | In force | High confidence | |
| US 9,102,671 | Compounds and Compositions as TRK Inhibitors In force · High confidence | In force | High confidence | |
| US 8,569,283 | Compounds and Compositions as C-Kit Kinase Inhibitors held by Novartis AG In force · High confidence | In force | High confidence | |
| US 9,199,981 | Compounds and Compositions as C-Kit Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,649,359 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 68 patents in force now held by others · 133 patents ended · 7 applications pending · 127 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.